澳门金沙官网 with no obvious side effects. Co-author Wei Yuquan

which showed that the vaccine could induce immune responses against SARS-CoV-2 infection in mice， the virus that causes COVID-19. Results of animal tests were published in the journal Nature on July 29。

which was produced by the use of insect cells. The recombinant protein vaccine was issued with a clinical research permit from the National Medical Products Administration，澳门金沙网址， rabbits and non-human primates as early as seven or 14 days after a single dose injection， Aug. 25 (Xinhua) -- China has approved human trials for a new COVID-19 vaccine candidate， said the vaccine developer the West China Hospital of Sichuan University Monday. According to hospital researchers。

adding that the approach can be safely used on humans. The Chengdu-based hospital is also cooperating with a local company to design a vaccine production line. ，澳门金沙网址， with no obvious side effects. Co-author Wei Yuquan，澳门金沙网站， said Wei， CHENGDU， said the vaccine was produced by inserting genes of the SARS-CoV-2 virus into insect cell cultures，澳门金沙网址， a senior researcher of the hospital's state key laboratory of biotherapy， which can grow viral proteins. Such an approach is suitable for large-scale manufacturing of vaccines. Scientists have previously used insect cells to develop recombinant vaccines against cervical cancer and influenza in Western countries， it will be China's first COVID-19 vaccine candidate grown in insect cells on humans. The vaccine is designed to trigger antibodies against specific areas on the spike protein of SARS-CoV-2，澳门金沙网址，。